Health care stocks were down late Tuesday afternoon with the NYSE Health Care Index fractionally lower and the Health Care Select Sector SPDR Fund (XLV) shedding 0.1%.
The iShares Biotechnology ETF (IBB) fell 1.4%.
In corporate news, Travere Therapeutics (TVTX) shares rose 13% after the company said it completed a meeting with the US Food and Drug Administration and plans to submit a supplemental new drug application for approval of Filspari as a potential treatment for focal segmental glomerulosclerosis, a rare kidney disorder.
Firefly Neuroscience (AIFF) shares surged 174% after it said it was accepted into Nvidia's (NVDA) Connect program.
Novartis (NVS) agreed to buy biopharmaceutical firm Anthos Therapeutics for up to $3.1 billion as the Swiss pharmaceutical giant expands its cardiovascular portfolio. Novartis shares added 0.8%.
Lipella Pharmaceuticals (LIPO) shares jumped 35% after it reported positive topline results from a phase 2a trial of LP-310, a liposomal-tacrolimus oral rinse for oral lichen planus.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。